Tirzepatide vs. Semaglutide: clinical decision-making in the GLP-1 landscape.
Semaglutide and tirzepatide are foundational options in obesity pharmacotherapy, with semaglutide providing cardiovascular protection and tirzepatide offering greater weight loss.
Where it sits
this study against the rest of the semaglutide corpusSummary and findings
This review compares semaglutide and tirzepatide in the context of obesity management. It synthesizes data from pivotal clinical trials to evaluate weight loss, metabolic, and cardiovascular benefits. No specific numeric findings are reported in the abstract.
Abstract
<h4>Background</h4>Obesity is a chronic disease with significant global health repercussions. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1RAs) are now established as evidence-based options for long-term obesity management. This review compares semaglutide and tirzepatide aims to support precise, equitable, and durable care for people with the disease of obesity.<h4>Areas covered</h4>This review provides clinicians with a comparative analysis of semaglutide (Ozempic) and tirzepatide (Mounjaro) in obesity management. We synthesize data from pivotal clinical trials (STEP, SELECT, SURMOUNT, SUMMIT) to guide evaluation of weight loss, metabolic, and cardiovascular benefits. Mechanistic differences, tolerability, and real-world implementation, including patient access and sustainability. The literature search was conducted using PubMed and Google Scholar and through a review of major international cardiology and endocrinology publications from 2020 to 2025.<h4>Expert opinion</h4>Semaglutide and tirzepatide represent foundational options in contemporary obesity pharmacotherapy. Semaglutide offers robust cardiovascular protection; tirzepatide yields greater weight loss and broad metabolic benefits. Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.
Background
The paper addresses the comparative effectiveness and decision-making processes regarding GLP-1 receptor agonists, specifically Tirzepatide and Semaglutide. Prior studies have indicated varying efficacy and safety profiles for these agents, making it essential to evaluate their clinical implications. Understanding how these medications influence treatment choices can guide practitioners in optimizing patient care.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.